



(12) Translation of
European patent specification

(11) NO/EP 3433232 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 207/48 (2006.01)
A61K 31/40 (2006.01)
A61P 1/04 (2006.01)
C07C 55/10 (2006.01)
C07C 57/15 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.08.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.15
(86)	European Application Nr.	17770545.6
(86)	European Filing Date	2017.03.17
(87)	The European Application's Publication Date	2019.01.30
(30)	Priority	2016.03.25, KR, 20160036081 2017.02.09, KR, 20170018336
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Daewoong Pharmaceutical Co., Ltd., 35-14, Jeyakgongdan 4-gil, Hyangnam-eup, Hwaseong-siGyenoggi-do 18623, Sør-Korea
(72)	Inventor	KIM, Aeri, DAEWOONG PHARMACEUTICAL CO., LTD.35-14, Jeyakgongdan 4- gilHyangnam-eupHwaseong-si, Gyeonggi-do 18623, Sør-Korea CHO, Kwan Hyung, 111-902, 156, Hwamyeongsindosi-roBuk-gu, Busan 46525, Sør-Korea
(74)	Agent or Attorney	Cosmovici Intellectual Property, 14 Rue du Rhône, 1204 GENÈVE, Sveits

(54)	Title	NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE
(56)	References Cited:	EP-A1- 1 803 709 WO-A2-2016/175555 CN-A- 104 447 491 US-A1- 2015 307 449 KR-B1- 101 613 245 US-A1- 2010 113 524 US-A1- 2011 288 040 KR-A- 20070 060 133

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

EP 3 433 232 B1

5 Påstander

1. en saltsyretilsetning 1-(5-(2,4-difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metyl- metanamin inneholdende ravsyre, vinsyre eller fumarsyre en metode for å preparere
- 10 2. en saltsyretilsetning 1-(5-(2,4-difluorofenyl)-1-((3-fluoropfenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin under påstand 1, bestående av følgende trinn:
- 1) 1 oppløse 1-(5-(2,4-difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin og en syre hver for seg i et organisk løsningsmiddel for å kunne
- 15 preparere en 1-(5-(2,4-difluorofenyl)-1-((3-fluorof- enyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanaminoppløsning og en syreoppløsning
- 2) 2 blande 1-(5-(2,4-difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin-løsningen og syreoppløsningen, deretter røre rundt
- 20 3. en metode for å preparere en saltsyretilsetning 1-(5-(2,4-difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy- 1H-pyrrol-3-yl)-N-metylmetanamin under påstand 2, inneholdende ravsyre, vinsyre eller fumarsyre
4. en metode for å preparere en saltsyretilsetning 1-(5-(2,4-difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy- 1H-pyrrol-3-yl)-N-metylmetanamin under påstand 2,
- 25 inneholdende ett eller flere organiske oppløsningsmidler fra gruppen bestående av n-heksan, etylcetat, butylacetat,
- 30 5. en farmasøytisk komposisjon for bruk i forebygging og behandling av gastrointestinal skade grunnet sår i gastrointestinaltrakten, gastritt, refluksøsofagitt eller helicobacter pylori (H. pylori), bestående av en saltsyretilsetning på 1-(5-(2,4- difluorofenyl)-1-((3-fluorofenyl)sulfonyl)-4-metoksy-1H-pyrrol-3-yl)-N-metylmetanamin under påstand 1